Asymptomatic and Symptomatic Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Insights from a Japanese Registry

Clicks: 1
ID: 313434
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #26 of 38 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Immune checkpoint inhibitors (ICIs) are a cornerstone of cancer therapy; however, immune-related adverse events, including myocarditis, pose significant challenges. Furthermore, limited data exist on the pathology of mild or asymptomatic cases. This study aimed to characterize the clinical, biomarker, and pathological features of ICI-associated cardiac toxicity, comparing symptomatic and asymptomatic cases within a Japanese multicenter registry. Methods A nationwide, retrospective registry collected data from 90 patients across 23 hospitals between 2020 and 2022. Patients were classified according to the American Society of Clinical Oncology Clinical Practice Guidelines: Grade 1 (asymptomatic) and Grade 2–4 (symptomatic). Endomyocardial biopsy was performed in 24 patients (n=19 symptomatic, n=5 asymptomatic). Results Among the enrolled patients (mean age: 68 years; 76.7% male), 41.1% were classified as Grade 1, whereas 58.9% were symptomatic (Grade 2–4). Symptomatic cases exhibited significantly higher troponin I and creatine kinase levels at onset. Pathological analysis revealed more extensive lymphocytic infiltration (CD3+ T cells) in symptomatic cases, particularly with higher CD8+ and CD68+ cell counts. Continuation of ICI therapy was more frequent in the asymptomatic group, and only one patient experienced recurrence. In contrast, all seven myocarditis-related deaths occurred in symptomatic patients. Conclusions This study provides one of the largest pathological and biomarker-based comparisons of symptomatic and asymptomatic ICI-associated cardiac toxicity. Our findings suggest that asymptomatic cases may represent a distinct, less aggressive inflammatory phenotype, characterized by lower CD8+ infiltration and limited myocardial damage.
Reference Key
openalex_W7161235656 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yudai Tamura, Yuichi Tamura, Hiroshi Otsu, Shiro Nakamori, Kazuaki Maruyama, Nao Muraoka, Masaaki Shoji, Kazuko Tajiri, Hirofumi Tomita, Yoshitaka Iso, Koichiro Sugimura, Hirotsugu Yamada, Koichiro Kinugawa, Ryota Morimoto, Hiroshi Akazawa, Kazumasa Harada, Shintaro Nakano, Kenichi Tsujita, Tadahiro Gunji, Toshihiro Tsuruda, Akihiro Nakamura, M Maruyama, Yuichi Miyake, Kunihiko Hatanaka, H KAWANO, Wakana Sato, Shingo Yano, Kyoko Imanaka-Yoshida, Issei Komuro
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag079
URL
https://doi.org/10.1093/ehjopen/oeag079
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.